Neurocrine Biosciences, Inc. (NBIX)
| Previous close | 108.29 |
| Open | 108.48 |
| Bid | 110.40 x 900 |
| Ask | 110.43 x 800 |
| Day's range | 108.48 - 110.58 |
| 52-week range | 75.25 - 129.29 |
| Volume | |
| Avg. volume | 803,303 |
| Market cap | 10.627B |
| Beta (5Y monthly) | 0.52 |
| PE ratio (TTM) | 184.23 |
| EPS (TTM) | 0.60 |
| Earnings date | 06 Feb 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 29 Dec 1995 |
| 1y target est | 127.75 |
- Zacks
Catalent (CTLT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Catalent (CTLT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy?
Neurocrine (NBIX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Motley Fool
Why Voyager Therapeutics Stock Is Sinking This Week
Shares of the gene therapy company Voyager Therapeutics (NASDAQ: VYGR) were down by a little over 18% from their intraweek high as of 11:44 a.m. ET Friday, according to data provided by S&P Global Market Intelligence. Rather, Voyager's shares seem to be reverting to the mean following their enormous run-up earlier this month. As a refresher, the biotech's shares spiked by as much as 76% during the first two weeks of January as a result of the company's lucrative gene therapy deal with Neurocrine Biosciences (NASDAQ: NBIX).
